Spots Global Cancer Trial Database for Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Official Title: Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Study ID: NCT04155749
Conditions
Study Description
Brief Summary: Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Arcellx, Inc.
Affiliation: Arcellx, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
